FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159822717> ?p ?o ?g. }

• W3159822717 abstract "Background COVID-19 Convalescent plasma (CCP) is safe and effective, particularly if given at an early stage of the disease. Our study aimed to identify an association between survival and specific antibodies found in CCP. Patients and Methods Patients ≥18 years of age who were hospitalized with moderate to severe COVID-19 infection and received CCP at the MD Anderson Cancer Center between 4/30/2020 and 8/20/2020 were included in the study. We quantified the levels of anti-SARS-CoV-2 antibodies, as well as antibodies against antigens of other coronavirus strains, in the CCP units and compared antibody levels with patient outcomes. For each antibody, a Bayesian exponential survival time regression model including prognostic variables was fit, and the posterior probability of a beneficial effect (PBE) of higher antibody level on survival time was computed. Results CCP was administered to 44 cancer patients. The median age was 60 years (range 37-84) and 19 (43%) were female. Twelve patients (27%) died of COVID-19-related complications. Higher levels of two non-SARS-CoV-2-specific antibodies, anti-HCoV-OC43 spike IgG and anti-HCoV-HKU1 spike IgG, had PBE = 1.00, and 4 SARS-CoV-2-specific antibodies had PBEs between 0.90 and 0.95. Other factors associated with better survival were shorter time to CCP administration, younger age, and female sex. Conclusions Common cold coronavirus spike IgG antibodies anti-HCoV-OC43 and anti-HCoV-HKU1 may target a common domain for SARS-CoV-2 and other coronaviruses. They provide a promising therapeutic target for monoclonal antibody production." @default.
• W3159822717 created "2021-05-10" @default.
• W3159822717 creator A5001914634 @default.
• W3159822717 creator A5002347804 @default.
• W3159822717 creator A5007244861 @default.
• W3159822717 creator A5022871468 @default.
• W3159822717 creator A5029989637 @default.
• W3159822717 creator A5030631684 @default.
• W3159822717 creator A5034104852 @default.
• W3159822717 creator A5036325470 @default.
• W3159822717 creator A5046115886 @default.
• W3159822717 creator A5048913229 @default.
• W3159822717 creator A5049475717 @default.
• W3159822717 creator A5053363095 @default.
• W3159822717 creator A5055885795 @default.
• W3159822717 creator A5056700648 @default.
• W3159822717 creator A5063600595 @default.
• W3159822717 creator A5067252491 @default.
• W3159822717 creator A5067777914 @default.
• W3159822717 creator A5075978876 @default.
• W3159822717 creator A5085763090 @default.
• W3159822717 creator A5090486222 @default.
• W3159822717 creator A5091033255 @default.
• W3159822717 date "2021-04-28" @default.
• W3159822717 modified "2023-10-18" @default.
• W3159822717 title "High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients" @default.
• W3159822717 cites W2057765075 @default.
• W3159822717 cites W2117969454 @default.
• W3159822717 cites W2170933940 @default.
• W3159822717 cites W2912436263 @default.
• W3159822717 cites W2948622157 @default.
• W3159822717 cites W3013742505 @default.
• W3159822717 cites W3015186638 @default.
• W3159822717 cites W3018023298 @default.
• W3159822717 cites W3022970339 @default.
• W3159822717 cites W3023088605 @default.
• W3159822717 cites W3025626988 @default.
• W3159822717 cites W3032677067 @default.
• W3159822717 cites W3034548712 @default.
• W3159822717 cites W3034816694 @default.
• W3159822717 cites W3037820956 @default.
• W3159822717 cites W3042183476 @default.
• W3159822717 cites W3047044993 @default.
• W3159822717 cites W3047109359 @default.
• W3159822717 cites W3047159181 @default.
• W3159822717 cites W3047848658 @default.
• W3159822717 cites W3049254735 @default.
• W3159822717 cites W3085153423 @default.
• W3159822717 cites W3089567185 @default.
• W3159822717 cites W3090049663 @default.
• W3159822717 cites W3096658347 @default.
• W3159822717 cites W3111431752 @default.
• W3159822717 cites W3115009914 @default.
• W3159822717 cites W3118278606 @default.
• W3159822717 cites W3128783047 @default.
• W3159822717 cites W3133101134 @default.
• W3159822717 cites W4210642183 @default.
• W3159822717 doi "https://doi.org/10.3389/fimmu.2021.675679" @default.
• W3159822717 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8113636" @default.
• W3159822717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33995420" @default.
• W3159822717 hasPublicationYear "2021" @default.
• W3159822717 type Work @default.
• W3159822717 sameAs 3159822717 @default.
• W3159822717 citedByCount "18" @default.
• W3159822717 countsByYear W31598227172021 @default.
• W3159822717 countsByYear W31598227172022 @default.
• W3159822717 countsByYear W31598227172023 @default.
• W3159822717 crossrefType "journal-article" @default.
• W3159822717 hasAuthorship W3159822717A5001914634 @default.
• W3159822717 hasAuthorship W3159822717A5002347804 @default.
• W3159822717 hasAuthorship W3159822717A5007244861 @default.
• W3159822717 hasAuthorship W3159822717A5022871468 @default.
• W3159822717 hasAuthorship W3159822717A5029989637 @default.
• W3159822717 hasAuthorship W3159822717A5030631684 @default.
• W3159822717 hasAuthorship W3159822717A5034104852 @default.
• W3159822717 hasAuthorship W3159822717A5036325470 @default.
• W3159822717 hasAuthorship W3159822717A5046115886 @default.
• W3159822717 hasAuthorship W3159822717A5048913229 @default.
• W3159822717 hasAuthorship W3159822717A5049475717 @default.
• W3159822717 hasAuthorship W3159822717A5053363095 @default.
• W3159822717 hasAuthorship W3159822717A5055885795 @default.
• W3159822717 hasAuthorship W3159822717A5056700648 @default.
• W3159822717 hasAuthorship W3159822717A5063600595 @default.
• W3159822717 hasAuthorship W3159822717A5067252491 @default.
• W3159822717 hasAuthorship W3159822717A5067777914 @default.
• W3159822717 hasAuthorship W3159822717A5075978876 @default.
• W3159822717 hasAuthorship W3159822717A5085763090 @default.
• W3159822717 hasAuthorship W3159822717A5090486222 @default.
• W3159822717 hasAuthorship W3159822717A5091033255 @default.
• W3159822717 hasBestOaLocation W31598227171 @default.
• W3159822717 hasConcept C10515644 @default.
• W3159822717 hasConcept C126322002 @default.
• W3159822717 hasConcept C159047783 @default.
• W3159822717 hasConcept C159654299 @default.
• W3159822717 hasConcept C203014093 @default.
• W3159822717 hasConcept C2777648638 @default.
• W3159822717 hasConcept C2779134260 @default.
• W3159822717 hasConcept C3007834351 @default.
• W3159822717 hasConcept C3008058167 @default.
• W3159822717 hasConcept C524204448 @default.

• next